Raffle A E, Alden B, Mackenzie E F
Bristol and District Health Authority, UK.
Lancet. 1995 Jun 10;345(8963):1469-73. doi: 10.1016/s0140-6736(95)91036-0.
We analysed rates of detection for smear abnormalities in 255,000 women served by the Bristol screening programme. The programme began in 1966 with the aim of eradicating the 30-40 deaths each year in Bristol from cervical cancer. Organisation has been good and population uptake has been high for the past 15 years. Records were computerised in 1977. During the 1988 to 1993 screening round, 225,974 women were tested. New smear abnormalities were found in 15,551, of whom nearly 6000 were referred for colposcopy. These numbers are excessively high in comparison with the incidence of the malignancy we are trying to prevent. The effect of screening on death rates in Bristol is too small to detect. Our conclusion is that despite good organisation of the service, much of our effort in Bristol is devoted to limiting the harm done to healthy women and to protecting our staff from litigation as cases of serious disease continue to occur. The real lesson from 30 years' cervical screening is that no matter how obvious the predicted benefit may seem for any screening test, introduction should never take place without adequate prior evaluation of both positive and negative effects in controlled trials.
我们分析了布里斯托尔筛查项目所服务的25.5万名女性涂片异常的检出率。该项目始于1966年,旨在消除布里斯托尔每年因宫颈癌导致的30至40例死亡。在过去15年里,组织工作良好,人群参与度很高。记录于1977年实现计算机化。在1988年至1993年的筛查周期中,对225,974名女性进行了检测。发现了15,551例新的涂片异常,其中近6000人被转诊进行阴道镜检查。与我们试图预防的恶性肿瘤发病率相比,这些数字过高。筛查对布里斯托尔死亡率的影响太小,无法检测到。我们的结论是,尽管该服务组织良好,但在布里斯托尔,我们的许多努力都致力于限制对健康女性造成的伤害,并保护我们的工作人员免受诉讼,因为严重疾病的病例仍在不断出现。30年宫颈癌筛查的真正教训是,无论任何筛查测试的预期益处看起来多么明显,如果没有在对照试验中对正面和负面影响进行充分的事先评估,就绝不应该开展。